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Strengths and limitations of this study
 ► This is the first population- based study to examine 
the extent and variability of vitamin D supplemen-
tation prescribing practice using representative pri-
mary care data.
 ► This study does not contain data from secondary 
care, however, vitamin D deficiency is largely man-
aged in the primary care setting.
 ► Although several explanations for the factors that 
might have contributed to changes in vitamin D 
supplementation prescribing over time are provided, 
it was not possible to determine the practitioners’ 
rationale for prescribing, nor could we assess the 
clinical appropriateness of prescriptions on an indi-
vidual level.
AbStrACt
Objective To examine temporal changes in the 
incidence and patterns of vitamin D supplementation 
prescribing by general practitioners (GPs) between 2008 
and 2016.
Design Population- based cohort study.
Setting UK general practice health records from The 
Health Improvement Network.
Participants Children aged 0 to 17 years who were 
registered with their general practices for at least 3 
months.
Outcome measures Annual incidence rates of vitamin 
D prescriptions were calculated, and rate ratios were 
estimated using multivariable Poisson regression to 
explore differences by sociodemographic factors. Data on 
the type of supplementation, dose, dosing schedule, linked 
25- hydroxyvitamin D (25(OH)D) laboratory test results and 
clinical symptoms suggestive of vitamin D deficiency were 
analysed.
results Among 2 million children, the crude annual 
incidence of vitamin D prescribing increased by 
26- fold between 2008 and 2016 rising from 10.8 
(95% CI: 8.9 to 13.1) to 276.8 (95% CI: 264.3 to 
289.9) per 100 000 person- years. Older children, 
non- white ethnicity and general practices in 
England (compared with Wales/Scotland/Northern 
Ireland) were independently associated with 
higher rates of prescribing. Analyses of incident 
prescriptions showed inconsistent supplementation 
regimens with an absence of pre- supplementation 
25(OH)D concentrations in 28.7% to 56.4% of 
prescriptions annually. There was an increasing 
trend in prescribing at pharmacological doses 
irrespective of 25(OH)D concentrations, deviating 
in part from UK recommendations. Prescribing at 
pharmacological doses for children with deficient 
status increased from 3.8% to 79.4%, but the rise 
was also observed in children for whom guidelines 
recommended prevention doses (0% to 53%). Vitamin 
D supplementation at pharmacological doses was also 
prescribed in at least 40% of children with no pre- 
supplementation 25(OH)D concentrations annually.
Conclusions There has been a marked and sustained 
increase in vitamin D supplementation prescribing in 
children in UK primary care. Our data suggests that 
national guidelines on vitamin D supplementation for 
children are not consistently followed by GPs.
IntrODuCtIOn
Vitamin D is an essential prohormone that 
humans obtain through cutaneous photo-
synthesis, diet or supplementation. While 
few would argue the importance of its physi-
ological role in maintaining calcium homeo-
stasis and bone mineralisation, the beneficial 
effects of vitamin D supplementation is a topic 
of much controversy.1–5 In children, severe 
vitamin D deficiency can cause rickets and 
hypocalcaemic seizures, but the clinical 
consequences of vitamin D insufficiency are 
less established despite the expanding liter-
ature in this area. Findings from numerous 
epidemiological studies have linked low 
25- hydroxyvitamin D (25(OH)D) concen-
trations to an increased risk of a myriad of 
adverse health consequences in both adults 
and children,6 7 where low concentrations 
in children have been linked to asthma,8 9 
eczema,10 respiratory tract infections11 12 and 
diabetes,13 among others.6 Yet, the majority 
of randomised controlled trials do not show 
improved outcomes with vitamin D supple-
mentation,6 7 14 15 and meta- analyses are 
inconclusive and widely debated.6–8 11 12 14–18
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Against this backdrop of ongoing debate, vitamin D 
deficiency is widely prevalent in all age groups and seen as 
a growing public health concern worldwide.19 The US,20 
Canada,21 Australia,22 23 France24 and the UK25 26 have all 
reported a significant increase in laboratory vitamin D 
testing, with as much as a 90- fold increase over a 10- year 
period.22 23 In England, there has also been a marked 
increase in the number of vitamin D prescriptions issued 
by general practitioners (GPs) in primary care, with 
annual spending on vitamin D prescriptions increasing 
from £0.5 to £40 million between 2007 and 2016,27 a rising 
trend that was partly attributed to vitamin D prescriptions 
issued for children.28
These reported trends have understandably led many 
to question the clinical appropriateness of vitamin D 
testing in practice.29 30 However, even though vitamin 
D is also widely available without a prescription, the 
increasing number of GPs issuing vitamin D prescrip-
tions has surprisingly not attracted the same degree of 
attention. For the UK where the healthcare service is 
publicly- funded and free, the national strategy is centred 
on primary prevention in managing vitamin D defi-
ciency. Specifically, UK national guidance (a summary 
of UK guidelines is presented in online supplemen-
tary table S1) has, until relatively recently, targeted 
recommendations on supplementation mainly towards 
high- risk groups.31–40 All children under 5 years of age 
including breastfed infants, if their mother is also at 
risk of vitamin D deficiency, were recommended to take 
daily vitamin D supplement at prevention doses.32–35 37 38 
There were no specific recommendations for children 5 
years or above unless individuals were considered at risk. 
In any children where 25(OH)D is tested, treatment at 
pharmacological doses is guided by whether 25(OH)D 
concentration is below 25 nmol/L, the threshold set by 
the UK Scientific Advisory Committee on Nutrition as 
vitamin D- deficient.31 39 Little is known about how well 
these recommendations are implemented in practice, 
but it has been noted that the complexity of the advice 
and poor communications may have caused confu-
sion among both health professionals and the public.37 
Considering there are numerous other international 
and national guidelines on vitamin D supplementation 
and health which differ in their definition of vitamin D 
deficiency and supplementation recommendations,41–43 
a comprehensive analysis of vitamin D prescribing by 
GPs offers an opportunity to facilitate the appropriate 
use of vitamin D supplementation for patient benefit and 
contain healthcare expenditure.
The aim of our study was to examine recent trends in 
prescribing patterns of vitamin D supplementation in 
children. We quantified temporal changes in the inci-
dence of vitamin D prescriptions issued by GPs in a UK 
population- based study. Moreover, we examined the 
proportions of prescriptions by type of supplementation, 
dose and dosing schedule, as well as the proportions that 
can be linked to 25(OH)D laboratory test results and clin-
ical symptoms suggestive of vitamin D deficiency.
MethODS
Data source
We obtained electronic health records from patients 
registered with UK general practices contributing to The 
Health Improvement Network (THIN). The THIN data-
base contains anonymised data from 744 general practices 
using the Vision computer system (In Practice Systems, 
London, UK). Data are from all patients in participating 
practices unless individual patients opt out of THIN. It 
contains data of approximately 16 million patients which 
has been shown to be broadly representative of the UK 
population in terms of age, sex, prevalence of medical 
conditions and mortality rates.44 As of 2015, the THIN 
dataset is reported to cover 6% of the UK population.45
THIN contains information on diagnoses, laboratory 
tests, symptoms and hospital referrals, as well as basic 
sociodemographic information. Clinical events and diag-
noses are recorded using a hierarchical coding system 
called Read codes.46 THIN also includes records of all 
prescriptions issued and these are linked to the British 
National Formulary. Prescribing data are particularly well 
recorded in THIN since the computerised entry made 
by the GP is directly used to issue a prescription to the 
patient. Prescribing data in THIN has been shown to 
be comparable to data on dispensed prescriptions with 
a mean practice redemption rate for all prescribing of 
98.5%.47
Study population
Study cohort selection is presented in online supplemen-
tary figure S1. We identified a cohort of children aged 0 
to 17 years registered with a THIN general practice from 1 
January 2008 to 31 December 2016. Individuals were not 
eligible to enter the study until 3 months after their regis-
tration with the practice in order to exclude those with 
prevalent prescriptions.48 Cohort entry was defined by the 
latest of: the study start date (1 January 2008); 3 months 
after the patient’s registration with the practice; or the 
date the practice met two predefined quality indicators 
(acceptable mortality recording and acceptable computer 
usage) for electronic data recording.49 50 Children with 
cystic fibrosis, chronic renal failure, inflammatory bowel 
diseases or chronic liver diseases were excluded as these 
conditions are known to affect vitamin D absorption or 
metabolism and therefore require specialist management 
(code lists for these conditions were created using a previ-
ously published methodology).51 Children were followed 
until an incident prescription of vitamin D, or censored 
on death, midpoint of their 18th birthday, end of registra-
tion with a practice, the last collection date of data from 
the practice or end of the study period (31 December 
2016), whichever occurred first. The total number of 
patient- years between cohort entry and exit defined the 
denominator for incidence calculations.
Outcome
A vitamin D prescription was defined as a first prescrip-
tion record (incident prescription) of either: a 
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single- ingredient product containing calciferol, ergocal-
ciferol or colecalciferol as the only active ingredient; or 
a combination product containing calciferol, ergocalcif-
erol or colecalciferol with other active ingredients (eg, 
ergocalciferol with calcium, multi- vitamin preparations). 
For the latter, only those that could be linked to a Read 
code indicating vitamin D deficiency or insufficiency or 
25(OH)D testing within 90 days either side of the date 
of the prescription were included. Comprehensive lists of 
drug codes and Read codes were developed using a previ-
ously published methodology (online supplementary 
tables S2 and S3).51 Incident cases were defined as chil-
dren with a first ever recording of a vitamin D prescrip-
tion in THIN during the study period. The date at which 
the first recording of vitamin D prescription was made 
was classified as the index date. Consultations where 
GPs did not issue a prescription but recommended self- 
purchase of over the counter vitamin D supplement were 
not considered as prescriptions.
Covariates
Age groups were defined as: up to 6 months; 6 months – 4 
years; 5–11; and 12–17 years. Ethnicity was grouped into 
the 2011 UK Census 5- category classification: children 
with multiple ethnicity records belonging to different 
categories were included in the analysis under the 
'missing data' category. Townsend index, an area- based 
relative measure of material deprivation, was extracted: 
the value closest to the start of the observation period was 
used for patients with multiple records. For this explor-
atory study, a pragmatic approach was taken to handle 
missing data separately under the 'missing data' category.
25(OH)D laboratory test results associated with inci-
dent prescriptions were identified by temporal proximity. 
A result was considered to be contemporary and would 
have formed the basis of prescribing if it occurred 90 days 
prior to the index date. Based on the elimination half- life 
of 25(OH)D, results recorded between 91–180 days after 
the index date were used to assess post- supplementation 
vitamin D status. Concentrations<25 nmol/L were catego-
rised as deficient as per the UK Department of Health 
and Social Care definition relevant at the time of the 
study period.31 Concentrations were further categorised 
as insufficient (25–50 nmol/L) as defined by the British 
Paediatric and Adolescent Bone Group and supported by 
the British Society of Paediatric Radiology and the Royal 
College of Paediatrics and Child Health.34 36 38
Read codes for symptoms or clinical complications 
that could potentially be related to vitamin D deficiency 
within the 90 days prior to the index date were extracted 
and organised into 12 categories as presented in online 
supplementary table S4.
Incident vitamin D prescriptions analyses
Children with multiple vitamin D prescriptions on the 
index date (534 patients) were excluded from prescrip-
tion pattern analyses as it was not possible to determine 
whether all prescriptions were relevant. Prescriptions 
were categorised according to the type of supplementa-
tion as per case definition above. Equivalent daily dose 
(EDD) was calculated for each incident prescription as 
determined by the quantity of vitamin D (international 
unit (IU)) prescribed per dose and the prescribed dosing 
frequency. Prescriptions with titration dosages (eg, two 
tablets daily for 2 weeks and then one tablet monthly) 
were handled by considering the first dosage only to 
capture the initial management strategy. Where unit of 
dosing was missing (eg, every day), one single dosing unit 
was assumed for tablet/capsule products only. Generic 
(eg, as directed) or ambiguous (eg, once daily for a liquid 
product) dosages were categorised under the ‘undeter-
mined’ category. EDDs were further categorised into 
dose bands. To assist interpretation, doses of 280–400 IU 
were considered prevention doses across all age groups 
based on recommendations relevant at the time of the 
study period.31 33–35 39 Doses between 401–1000 IU were 
categorised as a separate prevention dose category given 
divergent views exist within the medical community 
with regards to supplementation strategies for primary 
prevention.36–38 Doses between 1001 and 10 000 IU/day 
were considered as pharmacological treatment doses 
independent of age.36 38 Prescription quantity supplied in 
days was calculated based on total prescription quantity 
issued and corresponding dosage and capped at 365 days 
to take account of product shelf life. High- dose vitamin 
D regimens (stoss regimens) prescribed either as intra-
muscular injections or oral preparations were categorised 
separately and reported as either low dose (total dose 
<1 50 000 IU) or high dose (total dose ≥1 50 000 IU) stoss. 
As oral stoss regimens may be prescribed as a single dose 
or spread over several days, prescriptions with explicit 
duration directions for ≤15 days (eg, 5000 IU once daily 
for 14 days), or where the quantity prescribed were ≤7 
days with an equivalent daily dose ≥10 000 IU (eg, 5 
capsules of 20 000 IU with dosing direction 'one capsules 
once daily') were also categorised as stoss.
Statistical analysis
Cohort characteristics are presented by sex, ethnicity, 
socioeconomic quintile, country, calendar year and year 
of cohort entry as frequencies (%). Medians and IQR 
are presented for age at entry and follow- up time. We 
calculated crude annual incidence rates by dividing the 
number of children with a first ever recording of a vitamin 
D prescription by the Person Years at Risk. Confidence 
intervals (95% CI) were calculated assuming a Poisson 
distribution. Using Poisson regression, we estimated sex- 
stratified incidence rate ratios with 95% CI, adjusting for 
potential confounders. The time period was fitted as both 
a linear and categorical variable and models compared 
using the log likelihood ratio test: there was evidence that 
the categorised time period was a better fit with the data 
and thus the time period was treated as a categorical vari-
able. Age was also fitted as a categorial variable as it had 
a non- linear relationship. A fully adjusted sex- stratified 
model with an interaction between age and ethnicity 
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Table 1 Descriptive characteristics of the overall study 
cohort and incident cohort
Overall cohort
(n=2 051 403)
Incident cohort
(n=12 277)
Median age at entry, years 
(IQR)
5.5 (0.8–11.5) 7.6 (3.5–10.5)
Follow- up time, years (IQR) 3.5 (1.5–6.3) 4.2 (2–6.1)
Sex, n (%)     
  Male 1 055 395 (51.5) 4936 (40.2)
  Female 996 008 (48.6) 7341 (59.8)
Ethnicity, n (%)     
  White 878 360 (42.8) 2836 (23.1)
  Asian/Asian British 76 840 (3.8) 2928 (23.9)
  Black/African/Caribbean/
Black British
47 206 (2.3) 1275 (10.4)
  Other ethnic group 17 656 (0.9) 312 (2.5)
  Mixed/multiple ethnic group 28 605 (1.4) 295 (2.4)
  Missing 1 002 736 (48.9) 4631 (37.7)
Country of GP practice, n (%)     
  England 1 451 923 (70.8) 10 921 (88.9)
  Northern Ireland 84 171 (4.1) 177 (1.4)
  Scotland 310 142 (15.1) 597 (4.9)
  Wales 205 167 (10) 582 (4.7)
Townsend deprivation index 
quintile, n (%)
    
  1 (least deprived) 397 057 (19.4) 1452 (11.8)
  2 357 567 (17.4) 1377 (11.2)
  3 396 234 (19.3) 2128 (17.3)
  4 379 485 (18.5) 2740 (22.3)
  5 (most deprived) 291 502 (14.2) 2866 (23.3)
  Missing 229 558 (11.2) 1714 (14)
Year of cohort entry, n (%)     
  2008 1 060 098 
(51.7%)
6831 (55.6%)
  2009 130 610 (6.4%) 954 (7.8%)
  2010 126 825 (6.2%) 961 (7.8%)
  2011 160 853 (7.8%) 1020 (8.3%)
  2012 134 390 (6.6%) 870 (7.1%)
  2013 139 113 (6.8%) 757 (6.2%)
  2014 119 354 (5.8%) 503 (4.1%)
  2015 97 198 (4.7%) 279 (2.3%)
  2016 82 962 (4.0%) 102 (0.8%)
Children with no recorded data on ethnicity or Townsend index were 
categorised as ‘missing’.
IQR, IQR range.
was fitted and examined: while the interaction term was 
statistically significant, it did not change the estimates of 
the other variables and the incidence rates predicted by 
the two models were similar. However, as the model with 
the interaction term resulted in unstable predictions, the 
interaction term was not included in the final model. 
The final model with the inclusion of the GP practice as 
a random effect to account for any data clustering was 
used to calculate adjusted incidence rate ratios (IRRs). 
Proportions of prescriptions by type of supplementation, 
dose and dosing schedule, linked to 25(OH)D laboratory 
test concentrations and clinical symptoms suggestive of 
vitamin D deficiency, are presented as frequencies (%). 
Trends in prescribing characteristics were quantified 
using Spearman correlation coefficients using all years 
between 2008 and 2016. Data analysis was conducted 
using Stata 15 (Stata Corp, College Station, Texas, USA).
Three sensitivity analyses were performed. First, we 
considered a narrower case definition for vitamin D 
prescription, where only single- ingredient products were 
included. Second, we repeated the incidence analysis 
using complete cases only, that is among children who 
had complete data on sex, age, ethnicity, socioeconomic 
status, country and calendar year. Finally, we considered 
a broader definition for prevention doses, where equiva-
lent daily doses of ≤1000 IU were included.
Patient and public involvement
Patient and parent/carer representatives were involved 
in developing study plans and approving the lay summa-
ries for the grant supporting this study. Patients were not 
involved in setting the specific research question, the 
outcome measure, the design or implementation of this 
study. No patients were asked to advise on interpretation 
or writing up of results. It is not possible to disseminate 
the results of the research to study participants, but views 
from patient and parent/carer representatives will be 
sought in disseminating the research findings.
ethics
The THIN data collection scheme to obtain and provide 
anonymised patient data was approved by the National 
Health Service South- East Multicentre Research Ethics 
Committee (REC Reference: 04/MRE01/9) in 2002. The 
study protocol was approved by an independent Scientific 
Review Committee (Reference: 16THIN035).
reSultS
A total of 2 051 403 eligible children from 723 general 
practices contributed data between 1 January 2008 and 
31 December 2016, giving a total of 8 million person- years 
of follow- up. Of those children, 12 277 had an incident 
vitamin D prescription during the study period. Patient 
characteristics stratified by sex, ethnicity, country of 
general practice and socioeconomic status are shown in 
table 1 for the overall cohort and the incident cohort.
Crude incidence
The crude annual incidence of vitamin D prescribing in 
children increased by 26- fold between 2008 and 2016, 
rising from 10.8 (95% CI: 8.9 to 13.1) to 276.8 (95% CI: 
264.3 to 289.9) per 100 000 person- years. Figure 1A shows 
temporal trends in vitamin D prescribing in children 
alongside key national guidelines or reports on vitamin 
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Figure 1 (A)Time trends in vitamin D supplementation 
prescribing in children using all components of the case 
definition together and each source of case identification 
independently; (B) Time trends in vitamin D supplementation 
prescribing in children by different age groups. crude 
incidence rates with 95% confidence intervals represented 
by vertical bars. 2007: SACN: update on vitamin D31 2008: 
NICE: improving the nutrition of pregnant and breastfeeding 
mothers and children in low- income households32 2011: the 
National Diet and Nutrition Survey (NDNS) rolling programme: 
data from years 1 & 252 2012: Department of Health: Vitamin 
D advice on supplements for at risk groups33 2012: British 
Paediatric and Adolescent Bone Group’s position statement 
on vitamin D deficiency34 2012: RCPCH: vitamin D: position 
statement35 2013: RCPCH: guide for vitamin D in childhood36 
2014: NICE: vitamin D: increasing supplement use in at- risk 
groups37 2015: NOS: vitamin D and bone health38 2016: 
SACN: vitamin D and health report39 2016: NICE clinical 
knowledge summaries: vitamin D deficiency in children40 
SACN, Scientific Advisory Committee on Nutrition; NICE,The 
National Institute for Health and Care Eexcellence; RCPCH, 
Royal College of Paediatrics and Child Health; NOS, National 
Osteoporosis Society
D deficiency.31–40 52 Prescribing rates for females were 
higher than males, with an average ratio of male to female 
prescribing rate of 1:1.5 across all time periods. As can 
be seen from figure 1B, the increasing prescribing trend 
(rate per 100 000 person- years) was particularly apparent 
in children aged 12–17 years (14.8 (95% CI: 11.1 to 19.8) 
to 529.5 (95% CI: 499.2 to 561.7)), followed by those 
aged 5–11 years (7.8 (95% CI: 5.4 to 11.2) to 188.3 (95% 
CI: 172.5 to 205.5) ], 6 months–4 years (10.2 (95% CI: 
6.9 to 15.1) to 111.6 (95% CI: 96.8 to 128.7)), and less 
than 6 months (10.6 (95% CI: 1.5 to 75.2) to 79 (95% CI: 
32.9 to 189.7)). When vitamin D prescription was defined 
using single- ingredient vitamin D products only, we found 
similar trends to the main analysis (figure 1A).
Adjusted incidence rates
In multivariable analysis, increasing age, non- white 
ethnicity and social deprivation were associated with 
higher incidence rates of vitamin D prescribing (table 2). 
Among children aged 12–17 years, sex difference in 
incidence rate ratios was observed, with 1.8- fold higher 
vitamin D supplementation prescribing in females than 
males. General practices in England were also associated 
with higher IRRs as compared with Wales, Scotland and 
Northern Ireland. For both males and females, adjusted 
IRRs were higher than their corresponding crude values, 
with a 32- fold and 39- fold increase in the incidence of 
vitamin D prescribing between 2008 and 2016, respec-
tively. A sensitivity analysis using complete cases only was 
comparable to the main analysis, although the magnitude 
of the effects of ethnicity was marginally greater for both 
sexes, along with a smaller temporal difference in annual 
incidence rates (online supplementary table S5).
25-hydroxyvitamin D testing and presence of symptoms at 
initiation of supplementation
25(OH)D concentrations recorded before starting 
vitamin D supplementation are presented in figure 2A. 
Overall, 28.7% to 56.4% of prescriptions annually had 
no linked 25(OH)D results recorded in the 3 months 
prior to the index date. The proportion of children with 
laboratory- confirmed vitamin D deficiency (25(OH)
D<25 nmol/L) increased from 25.7% to 40.9% between 
2008 and 2011 before showing a gradual decrease to 
27.2% in 2016, coinciding with the issue of public health 
guidelines on primary prevention of vitamin D deficiency 
for at- risk individuals. Over the study period, increased 
prescribing of vitamin D supplementation was observed 
in children with insufficient status (25(OH)D between 
25–50 nmol/L]), increasing from 15.8% to 21.7% 
between 2008 and 2011 to 27.9% to 37.1% during the 
period between 2012 to 2016.
29.5% of children had symptoms related to vitamin 
D deficiency (online supplementary table S5). The 
most commonly recorded symptoms were those related 
to musculoskeletal or non- specific pain, tiredness or 
fatigue. In the group of children with no recorded pre- 
supplementation 25(OH)D results, only 15.4% had 
recorded symptoms.
types of supplementation
Overall, 109 different pharmaceutical preparations of at 
least 32 dosage strengths (eg, 3000 IU/mL, 20 000 IU/
tablet) were prescribed. A temporal change in supple-
mentation form was observed: colecalciferol products 
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Table 2 Multivariable poisson regression models of 
incidence of vitamin D supplementation prescribing in 
children stratified by sex.
Male Female
IRR* (95% CI) IRR* (95% CI)
Age group
  Up to 6 months 1.00 (Reference) 1.00 (Reference)
  6 months–4 years 1.93 (1.21 to 3.07) 1.28 (0.84 to 1.96)
  5–11 years 2.47 (1.55 to 3.92) 2.25 (1.48 to 3.42)
  12–17 years 4.15 (2.61 to 6.60) 7.41 (4.87 to 11.27)
Ethnicity   
  White 1.00 (Reference) 1.00 (Reference)
  Asian 5.05 (4.60 to 5.54) 4.46 (4.12 to 4.81)
  Black 2.83 (2.53 to 3.18) 2.83 (2.58 to 3.10)
  Others 2.68 (2.20 to 3.26) 2.72 (2.33 to 3.19)
  Mixed 1.93 (1.59 to 2.33) 1.84 (1.57 to 2.16)
  Missing 1.48 (1.37 to 1.61) 1.42 (1.33 to 1.52)
Townsend index   
  1 (least deprived) 1.00 (Reference) 1.00 (Reference)
  2 1.03 (0.92 to 1.17) 1.03 (0.94 to 1.14)
  3 1.18 (1.06 to 1.33) 1.20 (1.09 to 1.32)
  4 1.37 (1.22 to 1.53) 1.37 (1.25 to 1.51)
  5 (most deprived) 1.41 (1.25 to 1.59) 1.44 (1.31 to 1.59)
  Missing 1.38 (1.19 to 1.60) 1.43 (1.26 to 1.62)
Country   
  England 1.00 (Reference) 1.00 (Reference)
  Wales 0.34 (0.25 to 0.46) 0.33 (0.25 to 0.46)
  Scotland 0.24 (0.19 to 0.32) 0.18 (0.14 to 0.23)
  Northern Ireland 0.24 (0.16 to 0.37) 0.17 (0.11 to 0.27)
Year   
  2008 1.00 (Reference) 1.00 (Reference)
  2009 2.47 (1.73 to 3.51) 2.61 (1.93 to 3.52)
  2010 3.68 (2.63 to 5.15) 4.97 (3.75 to 6.58)
  2011 6.72 (4.88 to 9.25) 8.04 (6.12 to 10.56)
  2012 14.60 (10.72 to 19.90) 16.16 (12.39 to 2.08)
  2013 21.10 (15.52 to 28.67) 22.82 (17.53 to 29.72)
  2014 25.81 (18.99 to 35.09) 28.14 (21.60 to 36.65)
  2015 29.19 (21.44 to 39.76) 33.53 (25.70 to 43.74)
  2016 32.27 (23.64 to 44.05) 38.87 (29.75 to 50.80)
*Adjusted for all variables listed in the table. The multilevel models 
included the general practice as a random effect.
CI, confidence interval; IRR, incidence rate ratio.
Figure 2 (A) 25- hydroxyvitamin D concentrations recorded 
in the 90 days prior to or on the index date (n=12 277); (B) 
25- hydroxyvitamon D concentrations recorded between 91–
180 days after index date (only children with known levels, 
n=1035). Records with ambiguous unit of measurements 
were categorised as 'undetermined'.
accounted for 9.9% of the prescriptions in 2010 and 
increased to 90.2% in 2016, explaining the trends in 
prescribing patterns shown in figure 1 (online supple-
mentary figure S2).
Doses and frequencies of administration
The EDD prescribed ranged from 27 to 1 60 000 IU/day 
(prescribed doses by age group is summarised in online 
supplementary table S6) with a median duration of supply 
of 56 days (IQR: 30, 83 days). There were 237 (2.0%) 
prescriptions with doses less than the lowest recom-
mended primary prevention dose (<280 IU/day), and 
132 (1.1%) prescriptions with doses above the highest 
recommended pharmacological dose (>10 000 IU/day). 
A total of 24 different dosing frequencies were noted, 
with 37.2% of children on regimens other than once- daily 
dosing (online supplementary table S7).
Trend analysis of supplementation regimens strati-
fied by pre- supplementation 25(OH)D concentrations 
is presented in figure 3. Among children with defi-
ciency (25(OH)D<25 nmol/L), prescriptions with EDD 
>1000 IU/day, considered as pharmacological doses, 
showed a yearly increase from 3.8% in 2008 to 79.4% in 
2016 (Spearman’s rho=0.983, P<0.001), which is consis-
tent with UK recommendations. Increased used of 
pharmacological doses (0% in 2008 to 53% in 2016; Spear-
man’s rho=1, P<0.001) was also noted among children 
with 25(OH)D concentrations between 25–50 nmol/L 
who, according to UK national guidance, should have 
been recommended a supplement at prevention doses: 
the corresponding temporal decrease of prescriptions 
at prevention doses was noted irrespective of the cut- off 
value used to define prevention doses (400 or ≤1000 IU). 
A smaller but increased trend was similarly noted in the 
group of children with no linked 25(OH)D concen-
trations (35.7% in 2008 to 49.6% in 2016; Spearman’s 
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Figure 3 Dosages of incident vitamin D prescriptions 
presented in equivalent daily dose among children with: (A) 
no pre- supplementation 25(OH)D concentrations; (B) 25(OH)
D concentrations less than 25 nmol/L; and (C) 25(OH)D 
concentrations between 25–50 nmol/L in the 90 days prior to 
their incident prescriptions.
rho=0.7333, P=0.025). Overall, vitamin D supplementa-
tion at pharmacological doses (>1000 IU/day or stoss) 
was prescribed to 42.8% of children with insufficient 
status, outside of UK recommendations.
25-hydroxyvitamin D testing at follow-up
In the first 90 days post- initiation of vitamin D supple-
mentation, 9% (n=1109) of children had 25(OH)D 
concentrations recorded, of which 24.9% were recorded 
within 1 month after the index date, outside of guideline 
recommendations. Post- supplementation testing at the 
recommended time intervals was low; 25(OH)D results in 
the period between 91 to 180 days after incident prescrip-
tions were available for only 8.4% (n=1035) of children 
(figure 2B). Over the study period, the proportion of 
children with post- supplementation 25(OH)D concentra-
tions>50 nmol/L increased from 11.1% to 76.3%.
DISCuSSIOn
In a large cohort representative of children in UK primary 
care, there has been a marked temporal increase in 
vitamin D prescribing, even after adjustment for changes 
in population demographics. The adjusted incidence 
rates increased by 32- fold and 39- fold between 2008 
and 2016 for males and females, respectively. 25(OH)D 
concentrations for guiding supplementation were not 
available in more than 30% of children annually, and an 
increasing trend in prescribing vitamin D supplemen-
tation at pharmacological doses irrespective of 25(OH)
D concentrations was noted with wide variations in 
supplementation regimens prescribed, deviating in part 
from UK recommendations. Furthermore, with no clear 
evidence to support the use of vitamin D supplementa-
tion on health outcomes, other than for the prevention 
or treatment of rickets and osteomalacia, this aberrant 
prescribing practice incurs a huge, potentially avoidable, 
expense to our healthcare system.
This is the first study to report UK estimates of inci-
dence rates of vitamin D prescribing in children using 
a comprehensive case definition for vitamin D prescrip-
tion. An earlier study based in England included only 
156 general practices and reported a marked increase in 
the diagnosis of vitamin D deficiency and prescription 
costs of single- ingredient vitamin D products in children 
between 2000 and 2014.28 53 Our study reports similar 
trends but provides data from a much larger number of 
practices across the whole of the UK, with detailed socio- 
demographic prescribing patterns and extending the 
data to 2016.
Vitamin D prescribing in children increased sharply 
between 2011 and 2014, coinciding with the publication 
of guidelines and reports from the UK government and 
national guideline committees that emphasise the impor-
tance of vitamin D supplementation in certain groups of 
vulnerable children and young people.31–40 These have, 
in part, raised awareness of vitamin D deficiency among 
primary care practitioners, and explain the increase in 
vitamin D prescribing practices. Notably, the increase 
prescribing rates over time can be attributable primarily 
to children 5 years or older, suggesting widening aware-
ness of vitamin D deficiency, with risk perceptions 
among GPs going beyond children considered as high 
risk. The observed change in the type of supplementa-
tion prescribed, from ergocalciferol and combination 
products to colecalciferol products, is congruent with 
increased product availability of the latter27 and may 
potentially also relate to data suggesting colecalciferol is 
more efficacious at raising serum 25(OH)D concentra-
tions than ergocalciferol.54
Patient age, sex and ethnicity were identified as drivers 
for prescribing, in keeping with the higher prevalence 
rates of vitamin D deficiency reported in teenage girls, 
and non- white ethnic groups in the UK.39 Interestingly, we 
also observed increased rates of prescribing among prac-
tices in England compared with those in Wales (IRR=0.3), 
Scotland (IRR=0.2) and Northern Ireland (IRR=0.2), 
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suggesting other contextual factors influencing practi-
tioners’ prescribing behaviour. Disparities may be due to 
variations in regional strategies in implementing national 
guidelines, or differences in practitioners’ experience 
and attitudes towards vitamin D deficiency, and require 
further exploration.55–57
The initiation of vitamin D supplementation should be 
guided by 25(OH)D concentrations, except when used 
for primary prevention, as indicated in UK guideline 
recommendations.36 38 Yet, our results show an absence of 
25(OH)D results in more than 30% of prescriptions annu-
ally since 2009, a practice also reported by others.56 It is 
possible that a proportion of children may have 25(OH)
D concentrations checked and recorded by hospital 
clinicians, although children with conditions known to 
affect vitamin D absorption and metabolism and thus 
likely to receive secondary input, were already excluded 
in our analysis. We also recognised that a proportion of 
these prescriptions may have been intended for primary 
prevention. However, applying the most conservative 
primary prevention dose definition of ≤1000 IU/day, 
our finding that at least 40% of prescriptions exceeded 
1,000/day, and together with only a small number of chil-
dren with recorded symptoms possibly related to vitamin 
D deficiency, would be suggestive of aberrant prescribing.
Our analysis also found an upward trend in the 
prescribing of vitamin D supplementation at pharmaco-
logical doses independent of 25(OH)D concentrations. 
To some extent, this pattern observed for children with 
deficiency suggests that practitioners are responsive to 
prescribing guidelines,36 38 at least on a population level. 
On the other hand, a comparable increase was also seen 
in children with vitamin D insufficiency which deviates 
from UK national recommendations, and perhaps reflects 
confusion arising from multiple, sometimes conflicting, 
recommendations. At the same time, these deviations 
from recommendations might suggest a somewhat less 
cautious attitude towards the use of higher than recom-
mended doses of vitamin D among practitioners. Vitamin 
D has a wide therapeutic window and risk of toxicity is 
low, nevertheless the potential risk of vitamin D toxicity 
exists and requires further exploration given its wide-
spread, and sometimes unregulated use.
The major strength of our study is the large sample size 
that is representative of real- life clinical practice across 
the UK. Prescribing details in THIN are well recorded 
because all prescriptions from general practice are 
generated via a standardised computerised system. The 
inclusion of combination vitamin D products in the 
case definition also captures real- life clinical practice, 
but some cases could be missed if combination vitamin 
D product was prescribed but a diagnosis of vitamin D 
status was not entered in the primary care record. There 
are some limitations to our study too. The first vitamin D 
prescription recorded in THIN may not be the first ever 
prescription issued to the patient as initial prescribing 
may have occurred in secondary care and continued in 
general practice. However, most prescriptions issued by 
UK hospitals are limited to 7–14 days for clinically urgent 
conditions only, so the analysed sample is very likely to 
be representative of true practice. The study design did 
not allow us to determine the practitioner's rationale for 
prescribing, nor could we assess clinical appropriateness 
of prescriptions on an individual level. Trends in seasonal 
variations in prescribing were also not explored. Despite 
these limitations, our study explored the major clinical 
indicator for vitamin D supplementation, namely 25(OH)
D concentrations and the presence of symptoms.
Our study highlights two key implications for prac-
tice. First, diverse clinical practice highlights the need 
for a broader understanding of the multitude of factors 
influencing GPs’ prescribing decisions for vitamin D 
supplementation in order to reduce inappropriate 
prescribing.55 57 Further guidelines alone, even in the 
absence of ambiguity, are unlikely to be effective. Second, 
vitamin D supplementation exceeding recommended 
doses, and arguably, prescriptions at prevention doses 
may not be the best use of the limited health resources. 
On this basis, at least 32.3% of our prescriptions would 
fall into this category. Using the most conservative esti-
mate from an earlier study28 (£1.65 million for the total 
direct cost of vitamin D prescriptions in children per 
year), and without costing for consultation time with 
healthcare professionals, dispensing or tests, we estimate 
an annual saving of £0.5 million.
COnCluSIOn
There has been a marked and sustained increase in 
vitamin D prescribing in children in UK primary care. 
While this may reflect the success of the Department 
of Health and Social Care’s efforts in raising awareness 
of vitamin D deficiency, findings from our study would 
suggest that nationally set recommendations on vitamin 
D supplementation are not consistently followed by GPs, 
in terms of the number of patients treated, the doses used 
for supplementation, as well as the practice of prescribing 
vitamin D without appropriate testing. More recent NHS 
England guidance,30 that recommends prescribing phar-
macological doses of vitamin D supplementation only to 
those diagnosed with vitamin D deficiency, has the poten-
tial to reduce unnecessary prescriptions and UK health-
care expenditure, but its impact on prescribing practice 
would require further evaluation as previous guidelines 
have not always translated into practice.
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